National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Pancreatic Cancer

Pancreatic cancer is a disease that occurs when malignant (cancer) cells form in tissues of the pancreas.

There are two main types of pancreatic cancer that begin in different parts of the pancreas.

  • Most often, pancreatic cancer starts in the ducts that carry pancreatic juices; this type is called exocrine pancreatic cancer
  • Much less often, pancreatic cancer begins in the cells that make hormones; this type may be called endocrine pancreatic cancer or islet cell cancer

In advanced cases, pancreatic cancer cells may invade surrounding tissues or spread (metastasize) to other parts of the body via the blood stream or lymph system.

Pancreatic cancer represents the second most common GI cancer in the United States. It is estimated that 45,220* people in the United States will be newly diagnosed with pancreatic cancer in 2013.

Treatment options for pancreatic cancer vary depending on the stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Pancreatic Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with pancreatic cancer. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Pancreatic Cancer
Phase I
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
NCI-11-C-0099, NCT01294358

Principal Investigator:Referral Contact:
Udo RudloffMelissa Walker
301-496-3098301-402-9537
walkerme@mail.nih.gov


  
Trial and Protocol Number
Endocrine Tumor
No Phase
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCI-09-C-0242, NCT01005654

Principal Investigator:Referral Contact:
Electron KebebewErinn M. Hopkins
301-496-5049301-496-6457
erinn.hopkins@nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase II
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers
NCI-10-C-0166, NCT01174121

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
NCI-13-C-0046

Principal Investigator:Referral Contact:
Electron KebebewErinn M. Hopkins
301-496-5049301-496-6457
erinn.hopkins@nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
NCI-12-C-0111, NCT01583686

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction
NCI-12-C-0177, NCT01638533

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
NCI-12-C-0056, NCT01519817

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors
NCI-12-C-0008, NCT01439152

Principal Investigator:Referral Contact:
Raffit HassanYvonne Mallory
301-451-8742301-402-0255
malloryy@mail.nih.gov
Phase 0
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
NCI-11-C-0212, NCT01413451

Principal Investigator:Referral Contact:
Raffit HassanYvonne Mallory
301-451-8742301-402-0255
malloryy@mail.nih.gov
No Phase
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
NCI-12-C-0175, NCT01658917

Principal Investigator:Referral Contact:
Udai KammulaCarole Webb
301-435-8606301-402-8475
Webbcc@mail.nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111, NCT00452946

Principal Investigator:Referral Contact:
Deborah E. CitrinSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov